Skip to content

Study · Measured the body's own peptide · 2004

2 results

Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension.

Ye VZ, Hodge G, Yong JL, Duggan KA

European journal of pharmacology1 Feb 2004Cited by 14 (Europe PMC)

PMID14757146 (opens in a new tab)DOI10.1016/j.ejphar.2003.11.069 (opens in a new tab)PepBankPUB-14757146
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats with salt sensitive hypertension induced by L-NAME, 4 weeks of omapatrilat gave a higher myocardial VIP concentration than control.

    In plain wordsIn rats with high blood pressure, the body's own VIP in the heart was higher after omapatrilat than in untreated rats.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseMyocardial VIP concentration, omapatrilat versus control
    Study

    ratn: not reported in source

    L-NAME-induced salt sensitive hypertension
    Comparator
    Control
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Myocardial VIP was greater in omapatrilat than in controls (P<0.005) and enalapril-treated rats (P<0.05).
    1 context sentence
    Summary · context
    We compared the effects of 4 weeks treatment of the vasopeptidase inhibitor omapatrilat and the angiotensin converting enzyme inhibitor enalapril on the degree of fibrosis and the concentration of VIP in the heart in salt sensitive hypertension induced by treatment with L-nitro-omega-methylarginine (L-NAME).

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats with salt sensitive hypertension induced by L-NAME, 4 weeks of omapatrilat gave a higher myocardial VIP concentration than enalapril.

    In plain wordsIn rats with high blood pressure, the body's own VIP in the heart was higher after omapatrilat than after enalapril.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseMyocardial VIP concentration, omapatrilat versus enalapril
    Study

    ratn: not reported in source

    L-NAME-induced salt sensitive hypertension
    Comparator
    Enalapril
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Myocardial VIP was greater in omapatrilat than in controls (P<0.005) and enalapril-treated rats (P<0.05).
    1 context sentence
    Summary · context
    We compared the effects of 4 weeks treatment of the vasopeptidase inhibitor omapatrilat and the angiotensin converting enzyme inhibitor enalapril on the degree of fibrosis and the concentration of VIP in the heart in salt sensitive hypertension induced by treatment with L-nitro-omega-methylarginine (L-NAME).

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.